Julie A. Cullivan Sells 900 Shares of Axon Enterprise, Inc. (NASDAQ:AXON) Stock

Axon Enterprise, Inc. (NASDAQ:AXONGet Free Report) Director Julie A. Cullivan sold 900 shares of the stock in a transaction dated Thursday, September 5th. The shares were sold at an average price of $353.53, for a total transaction of $318,177.00. Following the completion of the transaction, the director now directly owns 3,653 shares of the company’s stock, valued at $1,291,445.09. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Axon Enterprise Stock Down 0.1 %

Shares of AXON traded down $0.24 during midday trading on Friday, hitting $354.62. The company had a trading volume of 509,146 shares, compared to its average volume of 518,284. The company’s 50 day moving average price is $330.20 and its 200 day moving average price is $310.26. The stock has a market cap of $26.76 billion, a price-to-earnings ratio of 102.36, a PEG ratio of 9.78 and a beta of 0.95. Axon Enterprise, Inc. has a 52 week low of $189.12 and a 52 week high of $378.89. The company has a quick ratio of 2.52, a current ratio of 2.88 and a debt-to-equity ratio of 0.35.

Axon Enterprise (NASDAQ:AXONGet Free Report) last released its earnings results on Tuesday, August 6th. The biotechnology company reported $1.20 earnings per share for the quarter, topping the consensus estimate of $1.02 by $0.18. The company had revenue of $504.00 million during the quarter, compared to the consensus estimate of $478.35 million. Axon Enterprise had a net margin of 16.06% and a return on equity of 9.34%. The company’s revenue was up 34.5% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.80 EPS. On average, equities research analysts predict that Axon Enterprise, Inc. will post 1.79 EPS for the current year.

Institutional Investors Weigh In On Axon Enterprise

Institutional investors have recently modified their holdings of the business. Blue Trust Inc. grew its position in shares of Axon Enterprise by 987.5% during the 2nd quarter. Blue Trust Inc. now owns 87 shares of the biotechnology company’s stock valued at $27,000 after buying an additional 79 shares during the last quarter. ICA Group Wealth Management LLC bought a new stake in shares of Axon Enterprise during the 4th quarter valued at about $26,000. Trivant Custom Portfolio Group LLC bought a new stake in shares of Axon Enterprise during the 1st quarter valued at about $31,000. First PREMIER Bank bought a new stake in shares of Axon Enterprise during the 1st quarter valued at about $33,000. Finally, Blue Bell Private Wealth Management LLC acquired a new position in Axon Enterprise during the 1st quarter valued at about $41,000. Institutional investors own 79.08% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on AXON. Jefferies Financial Group assumed coverage on shares of Axon Enterprise in a research report on Wednesday, July 17th. They set a “buy” rating and a $385.00 target price on the stock. Bank of America assumed coverage on shares of Axon Enterprise in a report on Wednesday, July 17th. They issued a “buy” rating and a $380.00 price target on the stock. Needham & Company LLC reiterated a “buy” rating and issued a $400.00 price target on shares of Axon Enterprise in a report on Wednesday, August 7th. Craig Hallum lifted their price target on shares of Axon Enterprise from $370.00 to $376.00 and gave the company a “buy” rating in a report on Wednesday, August 7th. Finally, Robert W. Baird lifted their price target on shares of Axon Enterprise from $355.00 to $360.00 and gave the company an “outperform” rating in a report on Wednesday, August 7th. Two equities research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company. According to MarketBeat.com, Axon Enterprise currently has an average rating of “Moderate Buy” and an average target price of $358.08.

View Our Latest Research Report on AXON

About Axon Enterprise

(Get Free Report)

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.

Recommended Stories

Insider Buying and Selling by Quarter for Axon Enterprise (NASDAQ:AXON)

Receive News & Ratings for Axon Enterprise Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axon Enterprise and related companies with MarketBeat.com's FREE daily email newsletter.